This strategy sets out an ambitious course of travel for the agency to 2025. It presents a vision to contribute to a healthier and more secure Europe, through better informed drug policy and action. Adopted unanimously by the agency’s key stakeholders in 2016, the strategy is the result of a year-long, in-depth analysis of the environment in which the EMCDDA operates. This analysis focused, in particular, on customer needs and a critical review of our internal capacity to meet them.
Tag
abuso
addiction
alcohol
alcol
analysis
arterie
brain
buprenorphine
cannabis
cell
coca
Cocaine
depression
Disease
drugs
EMCDDA
eroin
espad
EU
Fentanyl
hepatitis
hiv
Inhalants
Methylphenidate
naltrexone
Neurology
nida
opioid
opioids
Prevention
psychoactive
psychoactive substances
Research
schizophrenia
study
THC
tobacco
UNODC
virus
Tag
abuso
addiction
alcohol
alcol
analysis
arterie
brain
buprenorphine
cannabis
cell
coca
Cocaine
depression
Disease
drugs
EMCDDA
eroin
espad
EU
Fentanyl
hepatitis
hiv
Inhalants
Methylphenidate
naltrexone
Neurology
nida
opioid
opioids
Prevention
psychoactive
psychoactive substances
Research
schizophrenia
study
THC
tobacco
UNODC
virus